<DOC>
	<DOCNO>NCT02899052</DOCNO>
	<brief_summary>A Phase 2 , open-label , dose escalation study evaluate safety efficacy venetoclax combination carfilzomib-dexamethasone ( Kd ) participant relapse refractory MM receive 1 3 prior line therapy .</brief_summary>
	<brief_title>Study Venetoclax Combination With Carfilzomib Dexamethasone Subjects With Relapsed Refractory Multiple Myeloma ( MM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Eastern Collaborative Oncology Group ( ECOG ) performance score less equal 2 . Documented relapse progressive Multiple Myeloma ( MM ) regimen refractory recent line therapy . Received prior treatment least 1 , 3 , prior line therapy MM . Measurable disease Screening per International Myeloma Working Group ( IMWG ) criterion . Meets absolute neutrophil count , platelet count , hemoglobin , liver kidney function laboratory value within 2 week prior first dose study drug . Has preexist condition contraindicate include Nonsecretory oligosecretory MM Active plasma cell leukemia Waldenström 's macroglobulinemia Primary amyloidosis POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Active hepatitis B C infection base screen blood test Significant cardiovascular disease Major surgery within 4 week prior first dose Acute infection require parenteral therapy Peripheral neuropathy ≥ Grade 3 ≥ Grade 2 pain within 2 week prior first dose Uncontrolled diabetes uncontrolled hypertension within 14 day prior first dose Any medical condition , opinion Investigator , would adversely affect subject 's participation study . History active malignancy , include myelodysplastic syndrome ( MDS ) , within past 3 year prior study entry Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Refractory myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed myeloma</keyword>
</DOC>